References
Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an update perspective. Immunol Rev 237:264–283
Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147–1150
Sfikakis PP, Souliotis VL, Fragiadaki KG et al (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66–73
Fattorossi A, Battaglia A, Buzzonetti A et al (2005) Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116:134–141
Thiruppathi M, Rowin J, Li Jiang Q et al (2012) Functional defect in regulatory T cells in myasthenia gravis. Ann NY Acad Sci 1274:68–76
Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475–490
Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4:259–266
Díaz-Manera J, Martínez-Hernández E, Querol L et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189–193
Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23
Battaglia A, Buzzonetti A, Baranello C et al (2012) IL-21 synergises with IL-2 to enhance TCR-β-induced human T cell proliferation and counteracts IL-2/TGF-β induced regulatory T cell development. Immunology 139:109–120
Fattorossi A, Battaglia A, Ferrandina G et al (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:1418–1428
Khosroshahi A, Bloch DB, Deshpande V, Stone JH (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompts clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62:1755–1762
Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 10:236–247
Baran J, Kowalczyk D, Ozóg M, Zembala M (2001) Three-color flow cytometry detection of intracellular cytokines in peripheral blood mononuclear cells: comparative analysis of phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation. Clin Diagn Lab Immunol 8:303–313
Acknowledgments
This work was supported by a Catholic University grant (linea D.1) to A.E.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical standard
The Ethics Committee approved the off-label use of rituximab, the clinical and laboratory exams and the related study on 05/04/2011 (Protocol: P/237/CS/2011).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Catzola, V., Battaglia, A., Buzzonetti, A. et al. Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260, 2163–2165 (2013). https://doi.org/10.1007/s00415-013-6987-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-013-6987-y